Navigation Links
Dr. Jeffrey Freitag Appointed Chief Medical Officer of PharmaNet
Date:2/17/2011

PRINCETON, N.J., Feb. 17, 2011 /PRNewswire/ -- PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Jeffrey Freitag, M.D., Senior Vice President, PharmaNet Consulting, will expand his role to become Chief Medical Officer (CMO) of PharmaNet. In this position, he will be the senior medical representative for the Company and provide guidance to the Company's many physicians who are involved in designing and monitoring Phase I through Phase III clinical trials. He will also retain his current responsibilities heading PharmaNet's team of regulatory and pharmaceutical consultants which provide strategic drug development advice to clients."Excellence in pharmaceutical science and medicine is critical to the success of PharmaNet and its clients. We are therefore very pleased that Dr. Jeffrey Freitag, an accomplished internist and nephrologist, will be serving in the role of CMO," said Dr. Tom Newman, President of PharmaNet Development Group.

Dr. Freitag has worked in the pharmaceutical industry for over twenty-five years in a variety of positions including Vice President, Clinical Drug Development at The Liposome Company, Senior Vice President of Medical Affairs at PharmaNet and most recently as Vice President of Research & Development at Bone Care International before rejoining PharmaNet in 2006. Dr. Freitag is board certified in both Internal Medicine and Nephrology and has a strong academic, scientific and clinical background. He has extensive experience in providing medical and scientific direction and leadership to product development teams. He has also provided strategic clinical development consultation to clients in a variety of therapeutic areas including renal, pulmonary, cardiovascular, oncology and infectious disease therapeutic areas.

About PharmaNet Development Group, Inc.PharmaNet Development Group, a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com. Contact:  Anne-Marie HessPhone:   (609) 951-6842E-mail:   ahess@pharmanet.com
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. University Medical Pharmaceuticals Selects Jeffrey Ten as Senior Vice President, International Sales
2. Jeffrey Trotter Joins Pharmanet Development Group as Executive Vice President, Phase IV Development
3. Pfizers Jeffrey Kindler Becomes PhRMA Board Chairman; Christopher Viehbacher, John Lechleiter Assume New Posts
4. David Feldman, M.D. Appointed Co-Principal Investigator of DuraHeart(TM) Left Ventricular Assist System U.S. Clinical Trial
5. Autism Spectrum Therapies Co-Founder and Chief Clinical Officer Dr. William Frea Appointed to Board of Directors of Los Angeles Chapter of Autism Speaks
6. Wound Management Technologies Completes Acquisition of Secure eHealth, LLC and Other Assets from VirtualHealth Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
7. VirtualHealth Technologies Completes Sale of Secure eHealth, LLC and Other Assets to Wound Management Technologies; Robert Tapales Appointed President of Secure eHealth, LLC
8. Clive Dix Appointed as Chairman of Crescendo Biologics
9. Ruediger Naumann-Etienne Appointed to IRIDEX Board of Directors
10. Anesiva Announces Prospective Board Members To Be Appointed Upon Successful Completion of Proposed Merger
11. Pharmaceutical Industry Veteran is Appointed CMO at Kinex Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... , April 28, 2016 Oramed Pharmaceuticals ... clinical-stage pharmaceutical company focused on the development of oral drug ... the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... in New York . Nadav Kidron ... the conference. Presentation Details:   ...
(Date:4/28/2016)... New market research titled ... report that provides an overview of the Osteoarthritis,s ... identifying new targets and MOAs to produce first-in-class ... in this H1 2016 Osteoarthritis Pipeline report include ... Abiogen Pharma S.p.A., Ablynx NV, Achelios Therapeutics, Inc., ...
(Date:4/27/2016)... , April 27, 2016   ... 42% Growth in Recurring Consumable Sales  Clinical ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) inventor of ... its sales for the first quarter ended March 31, ... the execution of its commercial strategy. First ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... ... On Tuesday, April 26, 2016 members of the HomeTown Health network, a ... Deal on SB 258, the “Rural Health Care Relief” Bill. , The bill, which ... to individuals and corporations which donate directly to a “rural hospital” in Georgia, and ...
(Date:4/29/2016)... ... April 29, 2016 , ... The White House ... their loans, more information about their loan terms and accounts, and more protections ... debt, including federal and private loans, has reached $1.3 trillion, with 43 million ...
(Date:4/29/2016)... ... April 29, 2016 , ... A ... born with severe congenital diaphragmatic hernia have better survival rates if surgery is ... hernia (CDH)—a condition where the diaphragm fails to form completely, letting abdominal organs ...
(Date:4/29/2016)... ... 2016 , ... Mobility Designed is redefining mobility with their patent pending ... Crutch evenly distributes body weight from the elbow to the forearm. In consumer ... than with other crutches. , Co-founders Max and Liliana Younger were inspired to design ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Melanoma is the deadliest type of skin ... blame for the majority of skin cancer deaths. More than 10,000 people are expected to ... at diagnosis is 62, it is the one of the most commonly diagnosed cancers in ...
Breaking Medicine News(10 mins):